U.S. Chronic Kidney Disease Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: United States
- ✓Market: Chronic Kidney Disease Market
- ✓Market Size 2024: USD 52.6 billion
- ✓Market Size 2032: USD 78.9 billion
- ✓CAGR: 5.2%
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Model Net Pricing Early: Biopharma launch teams should, before the first quarter of 2026, model CKD drug revenue net of Medicare negotiated prices effective January 1, 2026 and the ESRD PPS bundle that absorbs oral-only drugs, because both now define dialysis-channel economics.
Chronic Kidney Disease in the U.S.: Market Overview
The U.S. chronic kidney disease market combines two linked revenue pools: pharmaceuticals that slow progression and treat anaemia and mineral-bone disorders, and dialysis and transplant services. The Centers for Disease Control and Prevention estimates that about 37 million American adults have CKD, and more than 800,000 people live with end-stage kidney disease. Public payers dominate because Medicare funds most dialysis care.
Government has been the dominant force in dialysis. The Social Security Amendments of 1972 (Public Law 92-603) created Medicare coverage for end-stage renal disease, and the Centers for Medicare and Medicaid Services (CMS) sets facility payment rates through the ESRD Prospective Payment System under 42 CFR Part 413. The private sector leads in drug development, with AstraZeneca, Bayer and Novo Nordisk launching CKD-indicated therapies, while DaVita and Fresenius Medical Care operate most in-centre capacity.
Policy-Driven Growth in U.S. Chronic Kidney Disease Care
The Inflation Reduction Act of 2022 (Public Law 117-169) is the most consequential demand-side mechanism. Its Medicare Drug Price Negotiation Program set maximum fair prices for Jardiance and Farxiga, both carrying CKD indications, effective January 1, 2026. Lower Part D cost-sharing for beneficiaries on SGLT2 inhibitors widens access to kidney-protective therapy, moving prescriptions into primary care and expanding the treated CKD population.
Executive Order 13878, Advancing American Kidney Health (July 10, 2019), set a target that 80 percent of new end-stage kidney disease patients receive home dialysis or a transplant by 2030. CMS operationalises that goal through the ESRD Treatment Choices Model, which pays providers for home dialysis performance. Separately, the Transitional Drug Add-on Payment Adjustment under the ESRD PPS reimburses qualifying new renal drugs above the bundled rate, accelerating adoption of novel anaemia and mineral-bone agents in dialysis facilities.
Regulatory Barriers and Compliance Costs
Entry into dialysis delivery is gated by state and federal permissions. New York's certificate-of-need process under Article 28 of the Public Health Law, administered by the New York State Department of Health, requires approval before a new dialysis facility opens, and reviews commonly exceed twelve months. Federally, facilities must meet the ESRD Conditions for Coverage at 42 CFR Part 494, surveyed by state agencies on CMS's behalf; non-compliance risks loss of Medicare certification.
Drug and device approvals add a second barrier. The FDA's Center for Drug Evaluation and Research approved vadadustat (Vafseo) in March 2024 for anaemia in dialysis patients with a boxed warning on cardiovascular risk. Haemodialysis systems require 510(k) clearance under 21 CFR 876.5820 from the FDA's Center for Devices and Radiological Health. Oral-only drugs now fall inside the ESRD PPS bundle from 2025, compressing manufacturer pricing.
Policy-Created Opportunities in U.S. Kidney Care
The Increasing Organ Transplant Access Model, run by the CMS Innovation Center and beginning July 1, 2025, creates a six-year payment framework for kidney transplant hospitals in selected regions. Transplant centres will procure immunosuppressants, organ perfusion systems and post-transplant monitoring under episode-based payments. The model rewards graft survival, favouring suppliers with outcome-linked contracts and transplant diagnostics.
The ESRD PPS and home dialysis incentives create demand for home-based equipment. Baxter International, a peritoneal dialysis cycler manufacturer, and Fresenius Medical Care gain volume as Medicare-funded home modalities expand toward the Advancing American Kidney Health target. Novo Nordisk's semaglutide received FDA approval for kidney failure risk reduction in type 2 diabetes in January 2025, and its 2027 Medicare negotiated price sets a clear future pricing pathway.
Regulatory and Policy Environment
Section 1881 of the Social Security Act (42 U.S.C. 1395rr) remains the statutory foundation of the Medicare end-stage renal disease programme, administered by the Centers for Medicare and Medicaid Services. CMS implements payment through the ESRD Prospective Payment System in 42 CFR Part 413 and facility standards through the Conditions for Coverage in 42 CFR Part 494. The Food and Drug Administration administers drug and device approval under the Federal Food, Drug, and Cosmetic Act.
The Inflation Reduction Act of 2022 (Public Law 117-169) adds Medicare Part D price negotiation. Negotiated prices for Jardiance and Farxiga take effect January 1, 2026, the next selected drug list publishes by February 1, 2026, and the semaglutide negotiated price takes effect January 1, 2027. Canada funds dialysis provincially under the Canada Health Act, while European approvals run through the EMA with national HTA reviews, whereas the U.S. relies on payer-led negotiation and federal bundling.
Long-Term Policy Outlook for CKD in the U.S.
By 2032, Medicare Part D price negotiation will cover a larger share of CKD prescribing as successive selection cycles reach additional kidney-relevant agents. Manufacturers will prioritise indications and formulations outside the negotiated scope, and branded CKD launches will rely increasingly on TDAPA add-on payments to recover early investment. Annual ESRD PPS updates will continue absorbing oral-only drugs, compressing dialysis-channel margins for pharmaceutical suppliers.
The 80 percent home dialysis or transplant target for new patients by 2030 will shift reimbursement toward home modalities, reshaping device demand toward home cyclers and remote monitoring. The ESRD Treatment Choices Model is scheduled to end in 2026, and the Kidney Care Choices Model runs through 2027. CMS must decide between permanent value-based kidney payment and a reversion to fee-for-service, a choice with direct consequences for provider capacity.
Market at a Glance
| Metric | Value |
|---|---|
| Market Size 2024 | USD 52.6 billion |
| Market Size 2032 | USD 78.9 billion |
| Growth Rate (CAGR) | 5.2% |
| Most Critical Decision Factor | Medicare reimbursement rate changes under ESRD PPS and IRA negotiation |
| Largest Region | South |
| Competitive Structure | Concentrated dialysis services; moderately concentrated pharmaceutical pipeline |
Leading Market Participants
- AstraZeneca
- Bayer
- Novo Nordisk
- Boehringer Ingelheim
- CSL Vifor
- Otsuka
- Akebia Therapeutics
- Ardelyx
- DaVita
- Fresenius Medical Care
Frequently Asked Questions
Market Segmentation
- SGLT2 Inhibitors
- Mineralocorticoid Receptor Antagonists
- Anemia Management Agents
- Phosphate Binders
- Vasopressin V2 Antagonists
- Outpatient Dialysis Facilities
- Home Dialysis
- Hospital Inpatient Dialysis
- Kidney Transplant Centres
- Nephrology Clinics
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.